In NSCLC patients, a number of predictive biomarkers (BRCA1, TP53, and KRAS) [4] have been identified as possible genetic risk factors that increase their susceptibility to developing lung cancer, which might be necessary for the development of treatments against the disease [5,6]. This evidence concerns the gene TP53 and lung carcinoma.